AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
capsaicin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| analgesics, capsaicin analogues | 3064 | 404-86-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 0.06 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0 % | Benet LZ, Broccatelli F, Oprea TI |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 54 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CDK9,DDR1,EIF2AK3,EPHB4,GRK2,MAP2K6,SIK2,STK33,TEK | 12 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Nov. 16, 2009 | FDA | ACORDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pain | 648.67 | 13.63 | 149 | 13527 | 4571 | 90610200 |
| Application site erythema | 192.39 | 13.63 | 58 | 13618 | 5150 | 90609621 |
| Body tinea | 182.34 | 13.63 | 46 | 13630 | 2102 | 90612669 |
| Inhibitory drug interaction | 160.13 | 13.63 | 45 | 13631 | 3118 | 90611653 |
| Purpura | 159.96 | 13.63 | 66 | 13610 | 14712 | 90600059 |
| Application site burn | 156.74 | 13.63 | 35 | 13641 | 939 | 90613832 |
| Infection susceptibility increased | 154.87 | 13.63 | 46 | 13630 | 3880 | 90610891 |
| Bone density decreased | 146.55 | 13.63 | 65 | 13611 | 17280 | 90597491 |
| Glucose tolerance impaired | 122.82 | 13.63 | 46 | 13630 | 7939 | 90606832 |
| Poor quality sleep | 121.84 | 13.63 | 64 | 13612 | 24629 | 90590142 |
| Application site vesicles | 111.67 | 13.63 | 29 | 13647 | 1488 | 90613283 |
| Skin disorder | 105.70 | 13.63 | 67 | 13609 | 36639 | 90578132 |
| Impaired work ability | 103.71 | 13.63 | 53 | 13623 | 19273 | 90595498 |
| Impaired quality of life | 102.98 | 13.63 | 56 | 13620 | 23088 | 90591683 |
| Occupational exposure to product | 92.66 | 13.63 | 28 | 13648 | 2503 | 90612268 |
| Hyperlipidaemia | 84.44 | 13.63 | 49 | 13627 | 22867 | 90591904 |
| Oral herpes | 71.98 | 13.63 | 51 | 13625 | 33473 | 90581298 |
| Carbuncle | 66.23 | 13.63 | 19 | 13657 | 1417 | 90613354 |
| Blood pressure systolic abnormal | 62.24 | 13.63 | 38 | 13638 | 19440 | 90595331 |
| Pigmentation disorder | 59.09 | 13.63 | 25 | 13651 | 5924 | 90608847 |
| Monoclonal immunoglobulin present | 58.90 | 13.63 | 19 | 13657 | 2105 | 90612666 |
| Hypothalamo-pituitary disorder | 57.80 | 13.63 | 19 | 13657 | 2233 | 90612538 |
| Blood pressure systolic increased | 56.49 | 13.63 | 56 | 13620 | 58289 | 90556482 |
| Application site warmth | 56.14 | 13.63 | 12 | 13664 | 261 | 90614510 |
| Burning sensation | 56.14 | 13.63 | 58 | 13618 | 63394 | 90551377 |
| Burns second degree | 56.08 | 13.63 | 18 | 13658 | 1962 | 90612809 |
| Cataract | 55.14 | 13.63 | 61 | 13615 | 72031 | 90542740 |
| Application site hyperaesthesia | 54.60 | 13.63 | 7 | 13669 | 0 | 90614771 |
| Urticaria thermal | 53.20 | 13.63 | 13 | 13663 | 520 | 90614251 |
| Renal cyst | 48.52 | 13.63 | 28 | 13648 | 12922 | 90601849 |
| Fibrosis | 46.10 | 13.63 | 21 | 13655 | 5931 | 90608840 |
| Administration site erythema | 41.80 | 13.63 | 12 | 13664 | 897 | 90613874 |
| Immune thrombocytopenia | 40.04 | 13.63 | 25 | 13651 | 13301 | 90601470 |
| Overweight | 39.95 | 13.63 | 19 | 13657 | 5915 | 90608856 |
| Blood pressure diastolic abnormal | 39.82 | 13.63 | 29 | 13647 | 19852 | 90594919 |
| Cellulitis | 37.77 | 13.63 | 57 | 13619 | 91280 | 90523491 |
| Wrist deformity | 36.86 | 13.63 | 15 | 13661 | 3223 | 90611548 |
| Herpes zoster | 36.24 | 13.63 | 57 | 13619 | 94587 | 90520184 |
| Limb injury | 35.72 | 13.63 | 33 | 13643 | 31475 | 90583296 |
| Weight increased | 33.34 | 13.63 | 138 | 13538 | 417789 | 90196982 |
| Dyslipidaemia | 33.01 | 13.63 | 20 | 13656 | 10087 | 90604684 |
| Application site discolouration | 32.72 | 13.63 | 10 | 13666 | 928 | 90613843 |
| Movement disorder | 32.13 | 13.63 | 30 | 13646 | 28989 | 90585782 |
| Burns first degree | 32.07 | 13.63 | 5 | 13671 | 15 | 90614756 |
| Nephropathy | 32.04 | 13.63 | 19 | 13657 | 9216 | 90605555 |
| Application site swelling | 31.81 | 13.63 | 9 | 13667 | 638 | 90614133 |
| Dyschromatopsia | 30.42 | 13.63 | 9 | 13667 | 748 | 90614023 |
| Body height decreased | 29.94 | 13.63 | 20 | 13656 | 11929 | 90602842 |
| Application site oedema | 28.13 | 13.63 | 5 | 13671 | 39 | 90614732 |
| Nail bed tenderness | 26.73 | 13.63 | 7 | 13669 | 371 | 90614400 |
| Systemic lupus erythematosus | 26.06 | 13.63 | 11 | 13665 | 361885 | 90252886 |
| Scratch | 25.90 | 13.63 | 17 | 13659 | 9849 | 90604922 |
| Application site discomfort | 25.71 | 13.63 | 7 | 13669 | 431 | 90614340 |
| Blood pressure increased | 25.09 | 13.63 | 76 | 13600 | 197141 | 90417630 |
| Blood viscosity abnormal | 24.67 | 13.63 | 6 | 13670 | 235 | 90614536 |
| Metamorphopsia | 24.63 | 13.63 | 9 | 13667 | 1448 | 90613323 |
| Toxicity to various agents | 23.71 | 13.63 | 7 | 13669 | 287839 | 90326932 |
| Application site hypoaesthesia | 23.40 | 13.63 | 3 | 13673 | 0 | 90614771 |
| Complement factor C4 decreased | 23.31 | 13.63 | 6 | 13670 | 297 | 90614474 |
| Contusion | 23.27 | 13.63 | 87 | 13589 | 251129 | 90363642 |
| Dizziness postural | 22.31 | 13.63 | 15 | 13661 | 9038 | 90605733 |
| Blood iron increased | 22.04 | 13.63 | 9 | 13667 | 1950 | 90612821 |
| Pemphigus | 21.87 | 13.63 | 11 | 13665 | 326853 | 90287918 |
| Thermal burn | 21.11 | 13.63 | 13 | 13663 | 6749 | 90608022 |
| Skin plaque | 21.00 | 13.63 | 15 | 13661 | 9960 | 90604811 |
| Throat irritation | 20.99 | 13.63 | 31 | 13645 | 48664 | 90566107 |
| Migraine with aura | 20.69 | 13.63 | 10 | 13666 | 3226 | 90611545 |
| Dysstasia | 20.54 | 13.63 | 22 | 13654 | 25030 | 90589741 |
| Vitamin B12 deficiency | 19.89 | 13.63 | 13 | 13663 | 7473 | 90607298 |
| Hepatic steatosis | 19.63 | 13.63 | 26 | 13650 | 36919 | 90577852 |
| Application site necrosis | 19.50 | 13.63 | 3 | 13673 | 8 | 90614763 |
| Blood pressure fluctuation | 19.27 | 13.63 | 31 | 13645 | 52382 | 90562389 |
| Wound | 19.09 | 13.63 | 11 | 13665 | 302969 | 90311802 |
| Hypertension | 18.96 | 13.63 | 126 | 13550 | 457406 | 90157365 |
| Heart rate decreased | 18.80 | 13.63 | 31 | 13645 | 53474 | 90561297 |
| Therapy non-responder | 18.63 | 13.63 | 54 | 13622 | 136650 | 90478121 |
| Glossodynia | 18.47 | 13.63 | 13 | 13663 | 321766 | 90293005 |
| Illness | 18.18 | 13.63 | 39 | 13637 | 81930 | 90532841 |
| Application site pruritus | 18.12 | 13.63 | 10 | 13666 | 4237 | 90610534 |
| Autonomic neuropathy | 17.59 | 13.63 | 7 | 13669 | 1420 | 90613351 |
| Cryoglobulinaemia | 17.49 | 13.63 | 6 | 13670 | 804 | 90613967 |
| Insomnia | 17.06 | 13.63 | 97 | 13579 | 333377 | 90281394 |
| Hand deformity | 16.97 | 13.63 | 12 | 13664 | 296350 | 90318421 |
| Secretion discharge | 16.77 | 13.63 | 16 | 13660 | 15880 | 90598891 |
| Urticaria contact | 16.60 | 13.63 | 3 | 13673 | 26 | 90614745 |
| Application site rash | 16.32 | 13.63 | 8 | 13668 | 2661 | 90612110 |
| Gastrointestinal procedural complication | 16.23 | 13.63 | 5 | 13671 | 477 | 90614294 |
| Application site haematoma | 16.21 | 13.63 | 3 | 13673 | 30 | 90614741 |
| Back pain | 16.05 | 13.63 | 92 | 13584 | 317083 | 90297688 |
| Joint stiffness | 16.02 | 13.63 | 36 | 13640 | 78006 | 90536765 |
| Vulvovaginal pruritus | 15.94 | 13.63 | 9 | 13667 | 3984 | 90610787 |
| Finger deformity | 15.73 | 13.63 | 22 | 13654 | 32875 | 90581896 |
| Cough | 15.51 | 13.63 | 102 | 13574 | 368860 | 90245911 |
| Burning mouth syndrome | 15.12 | 13.63 | 5 | 13671 | 598 | 90614173 |
| Oropharyngeal discomfort | 14.85 | 13.63 | 11 | 13665 | 7724 | 90607047 |
| Anti-cyclic citrullinated peptide antibody positive | 14.31 | 13.63 | 9 | 13667 | 236424 | 90378347 |
| Product preparation issue | 14.25 | 13.63 | 7 | 13669 | 2339 | 90612432 |
| Oxygen saturation decreased | 14.21 | 13.63 | 42 | 13634 | 107441 | 90507330 |
| Pericarditis | 14.12 | 13.63 | 12 | 13664 | 270139 | 90344632 |
| Dysuria | 14.07 | 13.63 | 23 | 13653 | 39378 | 90575393 |
| Myalgia | 14.06 | 13.63 | 58 | 13618 | 175067 | 90439704 |
| Skin burning sensation | 13.97 | 13.63 | 16 | 13660 | 19595 | 90595176 |
| Heart rate increased | 13.87 | 13.63 | 43 | 13633 | 112859 | 90501912 |
| Vulvovaginal swelling | 13.77 | 13.63 | 5 | 13671 | 791 | 90613980 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pain | 735.96 | 17.24 | 137 | 4223 | 2192 | 42614783 |
| Application site erythema | 166.55 | 17.24 | 41 | 4319 | 2525 | 42614450 |
| Burning sensation | 109.75 | 17.24 | 50 | 4310 | 20963 | 42596012 |
| Application site vesicles | 60.32 | 17.24 | 14 | 4346 | 668 | 42616307 |
| Sleep deficit | 45.79 | 17.24 | 12 | 4348 | 947 | 42616028 |
| Application site burn | 44.44 | 17.24 | 9 | 4351 | 224 | 42616751 |
| Application site warmth | 38.59 | 17.24 | 5 | 4355 | 3 | 42616972 |
| Quality of life decreased | 38.51 | 17.24 | 16 | 4344 | 5360 | 42611615 |
| Hyperaesthesia | 33.70 | 17.24 | 15 | 4345 | 5937 | 42611038 |
| Child abuse | 32.42 | 17.24 | 9 | 4351 | 883 | 42616092 |
| Application site discomfort | 31.48 | 17.24 | 6 | 4354 | 108 | 42616867 |
| Application site necrosis | 30.52 | 17.24 | 4 | 4356 | 3 | 42616972 |
| Epidural lipomatosis | 30.14 | 17.24 | 10 | 4350 | 1790 | 42615185 |
| Application site swelling | 30.09 | 17.24 | 7 | 4353 | 337 | 42616638 |
| Victim of child abuse | 29.87 | 17.24 | 9 | 4351 | 1180 | 42615795 |
| Pain | 29.33 | 17.24 | 72 | 4288 | 244776 | 42372199 |
| Drug ineffective | 29.08 | 17.24 | 134 | 4226 | 630063 | 41986912 |
| Application site paraesthesia | 27.74 | 17.24 | 4 | 4356 | 10 | 42616965 |
| Juvenile idiopathic arthritis | 26.40 | 17.24 | 10 | 4350 | 2629 | 42614346 |
| Glaucoma | 26.19 | 17.24 | 14 | 4346 | 8234 | 42608741 |
| Anticholinergic syndrome | 23.34 | 17.24 | 8 | 4352 | 1581 | 42615394 |
| Drug eruption | 20.96 | 17.24 | 18 | 4342 | 23057 | 42593918 |
| Swollen tongue | 20.18 | 17.24 | 17 | 4343 | 21214 | 42595761 |
| Osteoarthritis | 20.08 | 17.24 | 18 | 4342 | 24387 | 42592588 |
| Application site ulcer | 18.88 | 17.24 | 3 | 4357 | 17 | 42616958 |
| Inappropriate schedule of product administration | 18.14 | 17.24 | 34 | 4326 | 95868 | 42521107 |
| Electric shock sensation | 18.09 | 17.24 | 5 | 4355 | 483 | 42616492 |
| Tenderness | 17.35 | 17.24 | 11 | 4349 | 8872 | 42608103 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site pain | 878.75 | 15.11 | 193 | 15004 | 5306 | 110568796 |
| Application site erythema | 269.28 | 15.11 | 75 | 15122 | 5535 | 110568567 |
| Body tinea | 182.26 | 15.11 | 45 | 15152 | 2070 | 110572032 |
| Application site burn | 169.60 | 15.11 | 37 | 15160 | 980 | 110573122 |
| Bone density decreased | 153.91 | 15.11 | 64 | 15133 | 15978 | 110558124 |
| Infection susceptibility increased | 149.63 | 15.11 | 45 | 15152 | 4353 | 110569749 |
| Inhibitory drug interaction | 140.23 | 15.11 | 44 | 15153 | 4903 | 110569199 |
| Purpura | 134.18 | 15.11 | 66 | 15131 | 24322 | 110549780 |
| Application site vesicles | 133.37 | 15.11 | 33 | 15164 | 1531 | 110572571 |
| Glucose tolerance impaired | 117.67 | 15.11 | 46 | 15151 | 9791 | 110564311 |
| Poor quality sleep | 114.14 | 15.11 | 62 | 15135 | 28015 | 110546087 |
| Skin disorder | 104.29 | 15.11 | 68 | 15129 | 42845 | 110531257 |
| Impaired work ability | 98.21 | 15.11 | 55 | 15142 | 26364 | 110547738 |
| Impaired quality of life | 91.68 | 15.11 | 55 | 15142 | 29962 | 110544140 |
| Application site warmth | 79.54 | 15.11 | 16 | 15181 | 282 | 110573820 |
| Hyperlipidaemia | 75.55 | 15.11 | 52 | 15145 | 35796 | 110538306 |
| Burning sensation | 75.38 | 15.11 | 68 | 15129 | 69144 | 110504958 |
| Oral herpes | 68.27 | 15.11 | 49 | 15148 | 36031 | 110538071 |
| Carbuncle | 67.59 | 15.11 | 19 | 15178 | 1448 | 110572654 |
| Blood pressure systolic abnormal | 64.36 | 15.11 | 41 | 15156 | 24809 | 110549293 |
| Application site hyperaesthesia | 63.14 | 15.11 | 8 | 15189 | 0 | 110574102 |
| Blood pressure systolic increased | 57.89 | 15.11 | 64 | 15133 | 82927 | 110491175 |
| Monoclonal immunoglobulin present | 57.30 | 15.11 | 19 | 15178 | 2521 | 110571581 |
| Hypothalamo-pituitary disorder | 55.18 | 15.11 | 19 | 15178 | 2827 | 110571275 |
| Urticaria thermal | 54.45 | 15.11 | 13 | 15184 | 518 | 110573584 |
| Cataract | 53.21 | 15.11 | 60 | 15137 | 79425 | 110494677 |
| Administration site erythema | 51.58 | 15.11 | 12 | 15185 | 427 | 110573675 |
| Pigmentation disorder | 50.03 | 15.11 | 23 | 15174 | 7288 | 110566814 |
| Occupational exposure to product | 48.55 | 15.11 | 13 | 15184 | 826 | 110573276 |
| Application site swelling | 47.83 | 15.11 | 13 | 15184 | 874 | 110573228 |
| Application site paraesthesia | 43.53 | 15.11 | 8 | 15189 | 85 | 110574017 |
| Herpes zoster | 42.83 | 15.11 | 63 | 15134 | 108316 | 110465786 |
| Burns second degree | 42.74 | 15.11 | 21 | 15176 | 7712 | 110566390 |
| Blood pressure diastolic abnormal | 41.96 | 15.11 | 32 | 15165 | 25783 | 110548319 |
| Blood pressure increased | 41.29 | 15.11 | 102 | 15095 | 258271 | 110315831 |
| Overweight | 40.09 | 15.11 | 19 | 15178 | 6445 | 110567657 |
| Renal cyst | 39.80 | 15.11 | 27 | 15170 | 18145 | 110555957 |
| Wrist deformity | 38.44 | 15.11 | 15 | 15182 | 3174 | 110570928 |
| Cellulitis | 38.37 | 15.11 | 65 | 15132 | 125951 | 110448151 |
| Fibrosis | 37.08 | 15.11 | 19 | 15178 | 7623 | 110566479 |
| Weight increased | 36.84 | 15.11 | 134 | 15063 | 419510 | 110154592 |
| Application site discomfort | 36.36 | 15.11 | 9 | 15188 | 418 | 110573684 |
| Limb injury | 35.23 | 15.11 | 34 | 15163 | 37602 | 110536500 |
| Sleep deficit | 34.89 | 15.11 | 12 | 15185 | 1780 | 110572322 |
| Application site necrosis | 34.32 | 15.11 | 5 | 15192 | 9 | 110574093 |
| Movement disorder | 34.29 | 15.11 | 33 | 15164 | 36371 | 110537731 |
| Body height decreased | 33.93 | 15.11 | 20 | 15177 | 10543 | 110563559 |
| Application site discolouration | 32.54 | 15.11 | 10 | 15187 | 1039 | 110573063 |
| Application site oedema | 31.90 | 15.11 | 6 | 15191 | 73 | 110574029 |
| Immune thrombocytopenia | 30.37 | 15.11 | 25 | 15172 | 22469 | 110551633 |
| Child abuse | 29.82 | 15.11 | 9 | 15188 | 880 | 110573222 |
| Burns first degree | 29.33 | 15.11 | 5 | 15192 | 33 | 110574069 |
| Toxicity to various agents | 28.89 | 15.11 | 15 | 15182 | 480540 | 110093562 |
| Dyslipidaemia | 28.64 | 15.11 | 21 | 15176 | 15944 | 110558158 |
| Contusion | 28.09 | 15.11 | 83 | 15114 | 233278 | 110340824 |
| Application site hypoaesthesia | 27.91 | 15.11 | 4 | 15193 | 6 | 110574096 |
| Hyperaesthesia | 27.85 | 15.11 | 20 | 15177 | 14707 | 110559395 |
| General physical health deterioration | 27.52 | 15.11 | 12 | 15185 | 425283 | 110148819 |
| Nail bed tenderness | 27.27 | 15.11 | 7 | 15190 | 377 | 110573725 |
| Nephropathy | 27.11 | 15.11 | 19 | 15178 | 13448 | 110560654 |
| Victim of child abuse | 27.08 | 15.11 | 9 | 15188 | 1202 | 110572900 |
| Dyschromatopsia | 26.50 | 15.11 | 9 | 15188 | 1285 | 110572817 |
| Quality of life decreased | 26.24 | 15.11 | 19 | 15178 | 14150 | 110559952 |
| Therapy non-responder | 26.06 | 15.11 | 63 | 15134 | 157244 | 110416858 |
| Epidural lipomatosis | 25.90 | 15.11 | 10 | 15187 | 2057 | 110572045 |
| Blood iron increased | 25.30 | 15.11 | 10 | 15187 | 2188 | 110571914 |
| Blood viscosity abnormal | 24.80 | 15.11 | 6 | 15191 | 253 | 110573849 |
| Metamorphopsia | 24.45 | 15.11 | 9 | 15188 | 1624 | 110572478 |
| Insomnia | 24.26 | 15.11 | 106 | 15091 | 360484 | 110213618 |
| Pain | 24.13 | 15.11 | 218 | 14979 | 954737 | 109619365 |
| Complement factor C4 decreased | 22.79 | 15.11 | 6 | 15191 | 357 | 110573745 |
| Allodynia | 22.32 | 15.11 | 9 | 15188 | 2074 | 110572028 |
| Inappropriate schedule of product administration | 21.31 | 15.11 | 69 | 15128 | 203568 | 110370534 |
| Scratch | 20.89 | 15.11 | 16 | 15181 | 12963 | 110561139 |
| Dysstasia | 20.55 | 15.11 | 24 | 15173 | 32962 | 110541140 |
| Heart rate decreased | 20.46 | 15.11 | 39 | 15158 | 82717 | 110491385 |
| Thermal burn | 20.24 | 15.11 | 13 | 15184 | 7975 | 110566127 |
| Skin plaque | 19.08 | 15.11 | 15 | 15182 | 12630 | 110561472 |
| Finger deformity | 18.84 | 15.11 | 23 | 15174 | 33069 | 110541033 |
| Nasopharyngitis | 18.73 | 15.11 | 105 | 15092 | 394256 | 110179846 |
| Vulvovaginal pruritus | 18.27 | 15.11 | 9 | 15188 | 3322 | 110570780 |
| Illness | 18.23 | 15.11 | 37 | 15160 | 82134 | 110491968 |
| Migraine with aura | 17.87 | 15.11 | 9 | 15188 | 3483 | 110570619 |
| Vitamin B12 deficiency | 17.53 | 15.11 | 13 | 15184 | 10042 | 110564060 |
| Dizziness postural | 17.18 | 15.11 | 15 | 15182 | 14594 | 110559508 |
| Myalgia | 17.00 | 15.11 | 68 | 15129 | 222313 | 110351789 |
| Urticaria contact | 16.88 | 15.11 | 3 | 15194 | 26 | 110574076 |
| Gastrointestinal procedural complication | 16.86 | 15.11 | 5 | 15192 | 460 | 110573642 |
| Drug ineffective | 16.65 | 15.11 | 297 | 14900 | 1520243 | 109053859 |
| Application site exfoliation | 15.86 | 15.11 | 5 | 15192 | 565 | 110573537 |
| Back pain | 15.81 | 15.11 | 96 | 15101 | 370900 | 110203202 |
| Juvenile idiopathic arthritis | 15.77 | 15.11 | 10 | 15187 | 5997 | 110568105 |
| Fatigue | 15.67 | 15.11 | 244 | 14953 | 1215714 | 109358388 |
| Vulvovaginal swelling | 15.50 | 15.11 | 5 | 15192 | 608 | 110573494 |
| Cryoglobulinaemia | 15.36 | 15.11 | 6 | 15191 | 1273 | 110572829 |
| Lip swelling | 15.23 | 15.11 | 26 | 15171 | 50641 | 110523461 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M02AB01 | MUSCULO-SKELETAL SYSTEM TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN Capsaicin and similar agents |
| ATC | N01BX04 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, LOCAL Other local anesthetics |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:35674 | antihypertensive agent |
| CHEBI has role | CHEBI:38634 | voltage-gated sodium channel blocker |
| CHEBI has role | CHEBI:50919 | antiemetic |
| CHEBI has role | CHEBI:51177 | antitussive |
| CHEBI has role | CHEBI:63726 | neuroprotective agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:140535 | TRPV1 agonist |
| MeSH PA | D000982 | Antipruritics |
| MeSH PA | D003879 | Dermatologic Agents |
| MeSH PA | D018689 | Sensory System Agents |
Related Drugs by ATC class:
M02AB Capsaicin and similar agents 1 drug
N01BX Other local anesthetics 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postherpetic neuralgia | indication | 2177002 | |
| Neuralgia | indication | 16269008 | |
| Backache | indication | 161891005 | |
| Arthritic Pain | indication | ||
| Sprains and Strains | indication | ||
| Cannabis hyperemesis syndrome co-occurrent and due to cannabis abuse | off-label use | 11047881000119100 | |
| Cannabis hyperemesis syndrome co-occurrent and due to cannabis dependence | off-label use | 11048011000119100 | |
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Bacterial septicemia | contraindication | 10001005 | DOID:0040085 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Shock | contraindication | 27942005 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Body fluid retention | contraindication | 43498006 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Factor II deficiency | contraindication | 73975000 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Decreased respiratory function | contraindication | 80954004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Hemophilia | contraindication | 90935002 | |
| Disorder of skin | contraindication | 95320005 | DOID:37 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Open wound | contraindication | 125643001 | |
| Seizure disorder | contraindication | 128613002 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Heart block | contraindication | 233916004 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Denuded skin | contraindication | 418242004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.64 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Transient receptor potential cation channel subfamily V member 1 | Ion channel | OPENER | Ki | 8.22 | CHEMBL | CHEMBL | |||
| Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.42 | CHEMBL | |||||
| Cytochrome P450 1A2 | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
| Arachidonate 5-lipoxygenase | Enzyme | IC50 | 4.25 | CHEMBL | |||||
| Potassium voltage-gated channel subfamily A member 1 | Ion channel | IC50 | 4.54 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily M member 8 | Ion channel | IC50 | 6 | CHEMBL | |||||
| Lysine-specific histone demethylase 1A | Enzyme | IC50 | 6.22 | CHEMBL | |||||
| Tyrosine--tRNA ligase, cytoplasmic | Enzyme | Ki | 4.38 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily V member 1 | Ion channel | Ki | 5.77 | CHEMBL | |||||
| NADH-ubiquinone oxidoreductase chain 1 | Enzyme | IC50 | 4.28 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily M member 8 | Ion channel | IC50 | 4.55 | CHEMBL | |||||
| Transient receptor potential cation channel subfamily V member 1 | Ion channel | ACTIVATOR | EC50 | 8 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 7 | Ion channel | BLOCKER | IC50 | 4.60 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 1 | Ion channel | BLOCKER | IC50 | 4.50 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily A member 2 | Ion channel | BLOCKER | Kd | 4.40 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4019506 | VUID |
| N0000147626 | NUI |
| D00250 | KEGG_DRUG |
| 4019506 | VANDF |
| C0006931 | UMLSCUI |
| CHEBI:3374 | CHEBI |
| 4DY | PDB_CHEM_ID |
| CHEMBL294199 | ChEMBL_ID |
| DB06774 | DRUGBANK_ID |
| D002211 | MESH_DESCRIPTOR_UI |
| 1548943 | PUBCHEM_CID |
| 2486 | IUPHAR_LIGAND_ID |
| 10145 | INN_ID |
| S07O44R1ZM | UNII |
| 1992 | RXNORM |
| 169226 | MMSL |
| 4346 | MMSL |
| 6074 | MMSL |
| 001988 | NDDF |
| 400416009 | SNOMEDCT_US |
| 95995002 | SNOMEDCT_US |
| S07O44R1ZM | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Walgreens Arthritis Pain Relief Capsaicin Analgesic | HUMAN OTC DRUG LABEL | 1 | 0363-0837 | CREAM | 1 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Walgreens Roll-On | HUMAN OTC DRUG LABEL | 1 | 0363-1065 | GEL | 0.10 g | TOPICAL | OTC Monograph Drug | 8 sections |
| Heat Pain Relief | HUMAN OTC DRUG LABEL | 1 | 0363-6263 | CREAM | 0.10 g | TOPICAL | OTC Monograph Drug | 16 sections |
| Walgreens Capsaicin Hot Patch | HUMAN OTC DRUG LABEL | 1 | 0363-6691 | PATCH | 0.25 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Walgreens Capsaicin Hot | HUMAN OTC DRUG LABEL | 1 | 0363-9113 | PATCH | 0.60 mg | TOPICAL | OTC monograph not final | 13 sections |
| CAPSAICIN HEAT PATCHES BACK AND LARGE AREAS | HUMAN OTC DRUG LABEL | 1 | 0363-9902 | PATCH | 0.03 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Rugby Arthritis Pain RelievingTopical Analgesic | HUMAN OTC DRUG LABEL | 1 | 0536-1118 | CREAM | 0.75 mg | TOPICAL | OTC Monograph Drug | 15 sections |
| Rugby Capsaicin Cream | HUMAN OTC DRUG LABEL | 1 | 0536-1264 | CREAM | 0.10 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Capsaicin | HUMAN OTC DRUG LABEL | 1 | 0536-2525 | CREAM | 0.25 mg | TOPICAL | OTC Monograph Drug | 14 sections |
| Advil Targeted Relief | HUMAN OTC DRUG LABEL | 4 | 0573-6555 | CREAM | 0.25 mg | TOPICAL | OTC Monograph Drug | 16 sections |
| WellPatch Warming Pain Relief | HUMAN OTC DRUG LABEL | 1 | 10742-8127 | PATCH | 25 mg | TOPICAL | OTC Monograph Drug | 10 sections |
| CAPSAICIN HEAT PATCHES PAIN RELIEF | HUMAN OTC DRUG LABEL | 1 | 11822-4210 | PATCH | 0.03 g | TOPICAL | OTC Monograph Drug | 14 sections |
| RITE AID CAPSICUM HOT | HUMAN OTC DRUG LABEL | 1 | 11822-7448 | PATCH | 0.60 mg | TOPICAL | OTC monograph not final | 12 sections |
| Capsaicin | HUMAN OTC DRUG LABEL | 1 | 11822-7884 | CREAM | 0.00 g | TOPICAL | OTC Monograph Drug | 12 sections |
| ASTRAPHARM CHILLI BRAND | HUMAN OTC DRUG LABEL | 1 | 11993-000 | PLASTER | 0.25 g | TOPICAL | OTC Monograph Drug | 14 sections |
| ASTRAPHARM CHILLI BRAND EXTERNAL MEDICATED | HUMAN OTC DRUG LABEL | 1 | 11993-001 | PLASTER | 70 mg | TOPICAL | OTC monograph not final | 13 sections |
| BLUE SPRING Foot and Leg Comfort Cream with Pain Relief | HUMAN OTC DRUG LABEL | 2 | 14448-316 | CREAM | 0.25 mg | TOPICAL | OTC Monograph Drug | 13 sections |
| Dr. OH BALM | HUMAN OTC DRUG LABEL | 3 | 17452-430 | CREAM | 0.02 g | TOPICAL | OTC monograph not final | 9 sections |
| EARTHS CARE ARTHRITIS | HUMAN OTC DRUG LABEL | 1 | 24286-1559 | CREAM | 0.10 g | TOPICAL | OTC Monograph Drug | 13 sections |
| Overtime | HUMAN OTC DRUG LABEL | 3 | 27495-008 | LOTION | 0.02 g | TOPICAL | OTC Monograph Drug | 11 sections |
| Overtime | HUMAN OTC DRUG LABEL | 3 | 27495-008 | LOTION | 0.02 g | TOPICAL | OTC Monograph Drug | 11 sections |
| Dendracin Neurodendraxcin | HUMAN OTC DRUG LABEL | 3 | 27495-014 | LOTION | 0.02 g | TOPICAL | OTC Monograph Drug | 11 sections |
| Dendracin Neurodendraxcin | HUMAN OTC DRUG LABEL | 3 | 27495-014 | LOTION | 0.02 g | TOPICAL | OTC Monograph Drug | 11 sections |
| FLANAX | HUMAN OTC DRUG LABEL | 3 | 27854-499 | LINIMENT | 0.00 g | TOPICAL | OTC Monograph Drug | 10 sections |
| LaBella Linimento Obrero | HUMAN OTC DRUG LABEL | 3 | 31774-8005 | CREAM | 0.25 mg | TOPICAL | OTC monograph not final | 11 sections |
| MEDROX | HUMAN OTC DRUG LABEL | 2 | 33261-884 | PATCH | 0.04 g | TOPICAL | OTC MONOGRAPH NOT FINAL | 8 sections |
| ASSURED PAIN RELIEF HOT PATCH | HUMAN OTC DRUG LABEL | 2 | 33992-1889 | PATCH | 8.30 mg | TOPICAL | OTC monograph not final | 11 sections |
| Assured Pain Relief Hot Menthol | HUMAN OTC DRUG LABEL | 2 | 33992-6156 | PATCH | 8.30 mg | TOPICAL | OTC monograph not final | 10 sections |
| Kanjo Natural Pain relief oil | HUMAN OTC DRUG LABEL | 1 | 35192-040 | OIL | 0.08 g | TOPICAL | OTC Monograph Drug | 8 sections |
| Capsaicin | HUMAN OTC DRUG LABEL | 1 | 36800-729 | LIQUID | 0.15 g | TOPICAL | OTC monograph not final | 7 sections |